KRTX News

There are no companies scheduled for the holiday week ahead, and we likely won’t see any more IPOs until 2020. Lock-up periods will be expiring for seven companies. On Monday, December 23: Cambium Networks (CMBM). On Tuesday, December 24: Adaptive Biotechologies (ADPT), BridgeBio Pharma (BBIO), ...read more

Four recent biotech IPOs have soared more than 100% in the last 30 days, while four others have seen their stock prices halved. The highest flyer is June 2019 IPO Karuna Therapeutics (KRTX), up 282% over the past 30 days. In mid-November, Karuna disclosed positive results from its Phase 2 trial for schizophrenia drug KarXT, causing the stock to initially soar...read more

Eight companies raised $2.1 billion this past week, capping off the US IPO market's largest quarter in five years. The week was split between tech and biotechs, including two in the biotech space that went public at valuations of more than $2.0 billion. Over 10 companies submitted initial filings this past, promising an active July. This week, we also released our ...read more

Karuna Therapeutics, a Phase 2 biotech developing therapies for schizophrenia and other CNS disorders, raised $89 million by offering 5.6 million shares at $16, the midpoint of the $15 to $17 range. It had previously filed to offer 4.4 million shares. Karuna Therapeutics plans to list on the Nasdaq under the symbol KRTX. Goldman Sachs, Citi and Wells Fargo Securities acted as lead...read more